Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD

14.21  +0.02 (+0.14%)

After market: 14.21 0 (0%)

Fundamental Rating

7

INMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. INMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. A decent growth rate in combination with a cheap valuation! Better keep an eye on INMD. These ratings could make INMD a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

INMD had positive earnings in the past year.
In the past year INMD had a positive cash flow from operations.
Each year in the past 5 years INMD has been profitable.
In the past 5 years INMD always reported a positive cash flow from operatings.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

INMD has a better Return On Assets (25.23%) than 98.40% of its industry peers.
INMD has a Return On Equity of 28.44%. This is amongst the best in the industry. INMD outperforms 97.86% of its industry peers.
INMD's Return On Invested Capital of 16.27% is amongst the best of the industry. INMD outperforms 96.26% of its industry peers.
The Average Return On Invested Capital over the past 3 years for INMD is significantly above the industry average of 8.18%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(16.27%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROIC 16.27%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

INMD has a Profit Margin of 44.50%. This is amongst the best in the industry. INMD outperforms 97.86% of its industry peers.
In the last couple of years the Profit Margin of INMD has grown nicely.
INMD has a Operating Margin of 28.54%. This is amongst the best in the industry. INMD outperforms 96.26% of its industry peers.
In the last couple of years the Operating Margin of INMD has declined.
INMD has a better Gross Margin (79.98%) than 93.05% of its industry peers.
In the last couple of years the Gross Margin of INMD has declined.
Industry RankSector Rank
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
INMD has less shares outstanding than it did 1 year ago.
INMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.84
WACC8.82%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 9.60 indicates that INMD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.60, INMD belongs to the best of the industry, outperforming 91.98% of the companies in the same industry.
A Quick Ratio of 8.58 indicates that INMD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.58, INMD belongs to the top of the industry, outperforming 91.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.6
Quick Ratio 8.58
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

INMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.04%.
INMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.97% yearly.
The Revenue has decreased by -3.61% in the past year.
INMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.35% yearly.
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%

3.2 Future

Based on estimates for the next years, INMD will show a small growth in Earnings Per Share. The EPS will grow by 6.28% on average per year.
INMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.63% yearly.
EPS Next Y-3.16%
EPS Next 2Y3.68%
EPS Next 3Y6.28%
EPS Next 5YN/A
Revenue Next Year-5.17%
Revenue Next 2Y-0.02%
Revenue Next 3Y2.63%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.48, the valuation of INMD can be described as very cheap.
Based on the Price/Earnings ratio, INMD is valued cheaply inside the industry as 96.26% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.76, INMD is valued rather cheaply.
The Price/Forward Earnings ratio is 7.43, which indicates a rather cheap valuation of INMD.
96.26% of the companies in the same industry are more expensive than INMD, based on the Price/Forward Earnings ratio.
INMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.91, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 7.48
Fwd PE 7.43
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

INMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INMD is cheaper than 99.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, INMD is valued cheaper than 97.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.64
EV/EBITDA 1.76
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.33
EPS Next 2Y3.68%
EPS Next 3Y6.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (8/21/2025, 8:19:29 PM)

After market: 14.21 0 (0%)

14.21

+0.02 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners70.51%
Inst Owner Change-13.98%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap898.21M
Analysts72.31
Price Target16.58 (16.68%)
Short Float %6.41%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.54%
Min EPS beat(2)-13.69%
Max EPS beat(2)10.61%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-20.27%
Max EPS beat(4)10.61%
EPS beat(8)3
Avg EPS beat(8)-6.64%
EPS beat(12)7
Avg EPS beat(12)-0.75%
EPS beat(16)11
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-2.62%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-9.96%
Max Revenue beat(4)0.53%
Revenue beat(8)1
Avg Revenue beat(8)-7%
Revenue beat(12)5
Avg Revenue beat(12)-3.84%
Revenue beat(16)9
Avg Revenue beat(16)-1.49%
PT rev (1m)-4.69%
PT rev (3m)-12.36%
EPS NQ rev (1m)-14.74%
EPS NQ rev (3m)-29.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.13%
Revenue NQ rev (1m)-7.51%
Revenue NQ rev (3m)-12.09%
Revenue NY rev (1m)-1.1%
Revenue NY rev (3m)-1.34%
Valuation
Industry RankSector Rank
PE 7.48
Fwd PE 7.43
P/S 2.24
P/FCF 8.64
P/OCF 8.59
P/B 1.43
P/tB 1.43
EV/EBITDA 1.76
EPS(TTM)1.9
EY13.37%
EPS(NY)1.91
Fwd EY13.46%
FCF(TTM)1.65
FCFY11.58%
OCF(TTM)1.65
OCFY11.65%
SpS6.35
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)0.33
Profitability
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROCE 17.86%
ROIC 16.27%
ROICexc 79.63%
ROICexgc 79.63%
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
FCFM 25.9%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 81.89%
Cap/Sales 0.15%
Interest Coverage 250
Cash Conversion 90.67%
Profit Quality 58.19%
Current Ratio 9.6
Quick Ratio 8.58
Altman-Z N/A
F-Score7
WACC8.82%
ROIC/WACC1.84
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
EPS Next Y-3.16%
EPS Next 2Y3.68%
EPS Next 3Y6.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
Revenue Next Year-5.17%
Revenue Next 2Y-0.02%
Revenue Next 3Y2.63%
Revenue Next 5YN/A
EBIT growth 1Y-14.49%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-39.83%
EBIT Next 3Y-11.16%
EBIT Next 5YN/A
FCF growth 1Y-40.81%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-40.87%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%